Instructions for Authors 2020

General Policy. ANTICANCER RESEARCH (AR) will accept original high quality works and reviews on all aspects of experimental and clinical cancer research. The Editorial Policy suggests that priority will be given to papers advancing the understanding of cancer causation, and to papers applying the results of basic research to cancer diagnosis, prognosis, and therapy. Each article should include a concrete conclusion constituting of a “new piece of knowledge” backed up by scientific evidence. AR will also accept the following for publication: (a) Abstracts and Proceedings of scientific meetings on cancer, following consideration and approval by the Editorial Board; (b) Announcements of meetings related to cancer research; (c) Short reviews of scientific literature in the field of cancer research; (d) Announcements of newly received books and journals related to cancer, and (d) Announcements of awards and prizes.

The principal aim of AR is to provide prompt publication (print and online) for original works of high quality, generally within 1-2 months from final acceptance. Manuscripts will be accepted on the understanding that they report original unpublished works in the field of cancer research that are not under consideration for publication by another journal, and that they will not be published again in the same form. All authors should sign a submission letter confirming the approval of their article contents. All material submitted to AR will be subject to peer-review, when appropriate, by two members of the Editorial Board and by one suitable outside referee. All manuscripts submitted to AR are urgently treated with absolute confidence, with access restricted to the Managing Editor, the journal’s secretary, the reviewers and the printers. The Editors reserve the right to improve manuscripts on grammar and style.

The Editors and Publishers of AR accept no responsibility for the contents and opinions expressed by the contributors. Authors should warrant due diligence in the creation and issuance of their work.

NIH Open Access Policy. The journal acknowledges that authors of NIH-funded research retain the right to provide a copy of the published manuscript to the NIH four months after publication in ANTICANCER RESEARCH, for public archiving in PubMed Central.

Copyright. Once a manuscript has been published in ANTICANCER RESEARCH, which is a copyrighted publication, the legal ownership of all published parts of the paper has been transferred from the Author(s) to the journal. Material published in the journal may not be reproduced or published elsewhere without the written consent of the Managing Editor or Publisher.

Format. Two types of papers may be submitted: (i) Full papers containing completed original work, and (ii) review articles concerning fields of recognisable progress. Papers should contain all essential data in order to make the presentation clear. Reasonable economy should be exercised with respect to the number of tables and illustrations used. Papers should be written in clear, concise English. Spelling should follow that given in the “Shorter Oxford English Dictionary”.

Manuscripts. Submitted manuscripts exceeding 4 printed pages will be subject to excess page charges. The 4 printed pages correspond approximately to twelve (12) document pages (~250 words per double-spaced typed page in Arial 12), including abstract, text, tables, figures, and references. All manuscripts should be divided into the following sections: (a) First page including the title of the presented work [not exceeding fifteen (15) words], full names and full postal addresses of all Authors, name of the Author to whom proofs are to be sent, key words, an abbreviated running title, an indication “review”, “clinical”, “epidemiological”, or “experimental” study, and the date of submission. (Note: The order of the Authors is not necessarily indicative of their contribution to the work. Authors may note their individual contribution(s) in the appropriate section(s) of the presented work); (b) Abstract not exceeding 150 words, organized according to the following headings: Background/Aim – Materials and Methods/Patients and Methods – Results – Conclusion; (c) Introduction; (d) Materials and Methods/Patients and Methods; (e) Results; (f) Discussion; (g) Conflicts of Interest; (h) Authors’ contributions; (i) Acknowledgements; (j) References. All pages must be numbered consecutively. Footnotes should be avoided. Review articles may follow a different style according to the subject matter and the Author’s opinion. Review articles should not exceed 35 pages (approximately 250 words per double-spaced typed page) including all tables, figures, and references.

Figures. All figures should appear at the end of the submitted document file. Once a manuscript is accepted all figures and graphs should be submitted separately in either jpg, tiff or pdf format and at a minimum resolution of 300 dpi. Graphs must be submitted as pictures made from drawings and must not require any artwork, typesetting, or size modifications. Symbols, numbering and lettering should be clearly legible. The number and top of each figure must be indicated. Pages that include color figures are subject to color charges.

Tables. All tables should appear at the end of the submitted document file. Once a manuscript is accepted, each table should be submitted separately, typed double-spaced. Tables should be numbered with Roman numerals and should include a short title.


Clinical Trials. Authors of manuscripts describing clinical trials should provide the appropriate clinical trial number in the correct format in the text.

For International Standard Randomised Controlled Trials (ISRCTN) Registry (a not-for-profit organization whose registry is administered by Current Controlled Trials Ltd.) the unique number must be provided in this format: ISRCTNXXXXXXX (where XXXXXXX represents the unique number, always prefixed by “ISRCTN”). Please note that there is no space between the prefix “ISRCTN” and the number. Example: ISRCTN47956475.

For Clinicaltrials.gov registered trials, the unique number must be provided in this format: NCTXXXXXXX (where XXXXXXX represents the unique number, always prefixed by ‘NCT’). Please note that there is no space between the prefix ‘NCT’ and the number. Example: NCT00001789.

Ethical Policies and Standards. ANTICANCER RESEARCH agrees with and follows the “Uniform Requirements for Manuscripts Submitted to Biomedical Journals” established by the International Committee of Medical Journal Editors in 1978 and updated in October 2001 (www.icmje.org). Microarray data analysis should comply with the “Minimum Information About Microarray Experiments (MIAME) standard”. Specific guidelines are provided at the “Microarray Gene Expression Data Society” (MGED) website. Presentation of genome sequences should follow the guidelines of the NHGRI Policy on Release of Human Genomic Sequence Data. Research involving human beings must adhere to the principles of the Declaration of Helsinki and Title 45, U.S. Code of Federal Regulations, Part 46, Protection of Human Subjects, effective December 13, 2001. Research involving animals must adhere to the Guiding Principles in the Care and Use of Animals approved by the Council of the American Physiological Society. The use of animals in biomedical research should be under the careful supervision of a person adequately trained in this field and the animals must be treated humanely at all times. Research involving the use of human foetuses, foetal tissue, embryos and embryonic cells should adhere to the U.S. Public Law 103-41, effective December 13, 2001.

Submission of Manuscripts. Please follow the Instructions for Authors regarding the format of your manuscript and references. Manuscripts must be submitted only through our online submission system at: http://www.iiar-submissions.com/login.html

In case a submission is incomplete, the corresponding Author will be notified accordingly. Questions regarding difficulties in using the online submission system should be addressed to: email: journals@iiar-anticancer.org

Galley Proofs. Unless otherwise indicated, galley proofs will be sent to the corresponding Author of the submission. Corrections of galley proofs should be limited to typographical errors. Reprints, PDF files, and/or Open Access may be ordered after the acceptance of the paper. Authors of online open access articles are entitled to a complimentary online subscription to Anticancer Research for the current year and all previous digital content since 2004 (upon request to the Subscriptions Office). Galley proofs should be returned corrected to the Editorial Office by email (iiar@iiar-anticancer.org) within two days.

Specific information and additional instructions for Authors

1. Anticancer Research (AR) closely follows the new developments in all fields of experimental and clinical cancer research by (a) inviting reviews on topics of immediate importance and substantial progress in the last three years, and (b) providing the highest priority for rapid publication to manuscripts presenting original results judged to be of exceptional value. Theoretical papers will only be considered and accepted if they bear a significant impact or formulate existing knowledge for the benefit of research progress.

2. Anticancer Research will consider the publication of conference proceedings and/or abstracts provided that the material submitted fulfils the quality requirements and instructions of the journal, following the regular review process by two suitable referees.

3. An acknowledgement of receipt, including the article number, title and date of receipt is sent to the corresponding author of each manuscript upon receipt. If this receipt is not received within 20 days from submission, the author should call or write to the Editorial Office to ensure that the manuscript (or the receipt) was not lost in the mail or during electronic submission.

4. Each manuscript submitted to AR is sent for peer-review in confidence to two-three suitable referees with the request to return the manuscript with their comments to the Editorial Office within 12 days from receipt. If reviewers need a longer time or wish to send the manuscript to another expert, the manuscript may be returned to the Editorial Office with a delay. All manuscripts submitted to AR, are treated in confidence, without access to any person other than the Managing Editor, the journal’s secretary, the reviewers and the printers.
5. All accepted manuscripts are carefully corrected in style and language, if necessary, to make presentation clear. (There is no fee for this service). Every effort is made (a) to maintain the personal style of the author’s writing and (b) to avoid change of meaning. Authors will be requested to examine carefully manuscripts which have undergone language correction at the pre-proof or proof stage.

6. Authors should pay attention to the following points when writing an article for AR:
   • The Instructions to Authors must be followed in every detail.
   • The presentation of the experimental methods should be clear and complete in every detail facilitating reproducibility by other scientists.
   • The presentation of results should be simple and straightforward in style. Results and discussion should not be combined into one section, unless the paper is short.
   • Results given in figures should not be repeated in tables.
   • Figures (graphs or photographs) should be prepared at a width of 8 or 17 cm with legible numbers and lettering.
   • Photographs should be clear with high contrast, presenting the actual observation described in the legend and in the text. Each legend should provide a complete description, being self-explanatory, including technique of preparation, information about the specimen and magnification.
   • Statistical analysis should be elaborated wherever it is necessary. Simplification of presentation by giving only numerical or % values should be avoided.
   • Fidelity of the techniques and reproducibility of the results, should be points of particular importance in the discussion section. Authors are advised to check the correctness of their methods and results carefully before writing an article. Probable or dubious explanations should be avoided.
   • Authors should not cite results submitted for publication in the reference section. Such results may be described briefly in the text with a note in parenthesis (submitted for publication by… authors, year).
   • References. Each article should address, list and discuss the entire spectrum of current publications relevant to its field.
   • By following these instructions, Authors will facilitate a more rapid review and processing of their manuscripts and will provide the readers with concise and useful papers.

7. Following review and acceptance, a manuscript is examined in language and style, and galley proofs are rapidly prepared. Second proofs are not sent unless required.

8. Authors should correct their galley proofs very carefully and preferably twice. An additional correction by a colleague always proves to be useful. Particular attention should be paid to chemical formulas, mathematical equations, symbols, medical nomenclature etc. Any system of correction marks can be used in a clear manner, preferably with a red pen. Additions or clarifications are allowed provided that they improve the presentation but do not bring new results (no fee).

9. Articles submitted to AR may be rejected without review if:
   • they do not fall within the journal’s policy.
   • they do not follow the instructions for authors.
   • language is unclear.
   • results are not sufficient to support a final conclusion.
   • results are not objectively based on valid experiments.
   • they repeat results already published by the same or other authors before the submission to AR.
   • plagiarism is detected by plagiarism screening services.
   (Rejection rate (2016): 66%).

10. Authors who wish to prepare a review should contact the Managing Editor of the journal in order to get confirmation of interest in the particular topic of the review. The expression of interest by the Managing Editor does not necessarily imply acceptance of the review by the journal.

11. Authors may inquire information about the status of their manuscript(s) by calling the Editorial Office at +30-22950-53389, Monday to Friday 9:00-16:00 (Athens time), or by sending an e-mail to journals@iiar-anticancer.org

12. Authors who wish to edit a special issue on a particular topic should contact the Managing Editor.

13. Authors, Editors and Publishers of books are welcome to submit their books for immediate review in AR. There is no fee for this service.

(Copyright© 2020 - International Institute of Anticancer Research (G.J. Delinasios). All rights reserved (including those of translation into other languages). No part of this journal may be reproduced, stored in a retrieval system, or transmitted in any form or by any means, electronic, mechanical, photocopying, microfilming, recording or otherwise, without written permission from the Publisher.)
General Policy

**CANCER GENOMICS & PROTEOMICS** (CGP) welcomes submissions of original high quality articles and reviews on all aspects of the application of genomic and proteomic technologies to experimental and clinical cancer research. The journal's scientific spectrum includes: (a) molecular causes of carcinogenesis, cancer progression and metastasis; (b) structural and functional aspects of genes in the cancer cell; (c) advances in genomic and proteomic technologies applicable to cancer research; (d) anticancer drug design and drug development. A main aim of CGP is to ensure the prompt and confidential review, and rapid publication of original works and reviews, generally within 1-3 months from submission.

CGP is published bimonthly by the International Institute of Anticancer Research (IIAR) and is available online only and open access with Stanford University HighWire Press. For more information please visit our website www.cgp.iiarjournals.org.

**Editorial Office:** International Institute of Anticancer Research, 1st km Kapandritiou-Kalamou Rd., P.O. Box 22, Kapandriti, Attiki 19014, Greece. Tel: +30 22950 52945, Fax: +30 22950 53389.

U.S. Branch: Anticancer Research Inc., USA, 111 Bay Avenue, Highlands, NJ, USA.

**E-mail:** journals@iiar-anticancer.org; IIAR WEBSITES: www.iiar-anticancer.org and www.iiarjournals.org

### Selection of Recent Articles


Pazopanib Inhibits Tumor Growth, Lymph-node Metastasis and Lymphangiogenesis of an Orthotopic Mouse of Colorectal Cancer. G. ZHU, M. ZHAO, Q. HAN, Y. TAN, Y. SUN, M. BOUVET, S.R. SINGH, J. YE, R.M. HOFFMAN (San Diego, CA; Frederick, MD, USA; Fuzhou, PR China)


Chromosome Translocation t(14;21)(q11;q22) Activates Both OLG1 and OLIG2 in Pediatric T-cell Lymphoblastic Malignancies and May Signify Adverse Prognosis. I. PANAGOPoulos, L. GORUNOVA, I.M. RINVOLL JOHANSDOTTIR, K. ANDERSEN, A. HOLTH, K. BEISKE, S. HEIM (Oslo, Norway)


Significant Association Between the MiR146a Genotypes and Susceptibility to Childhood Acute Lymphoblastic Leukemia in Taiwan. J.-S. PEI, W.-S. CHANG, P.-C. HSU, C.-C. CHEN, Y.-T. CHIN, T.-L. HUANG, Y.-N. HSU, C.-C. KUO, Y.-C. WANG, C.-W. TSAI, C.-L. GONG, D.-T. BAU (Taoyuan; Taichung, Taiwan; ROC)


MicroRNAs Involved in Metastasis of Hepatocellular Carcinoma: Target Candidates, Functionality and Efficacy in Animal Models and Prognostic Relevance. U.H. WEIDLE, D. SCHMID, F. BIRZLE, U. BRINKMANN (Fenzenberg, Germany; Basel, Switzerland)

Increased Expression of Gremlin1 Promotes Proliferation and Epithelial Mesenchymal Transition in Gastric Cancer Cells and Correlates With Poor Prognosis of Patients With Gastric Cancer. Z. SUN, S. CAI, C. LIU, Y. CUI, J. JI, W.G. JIANG, L. YE (Cardiff, UK; Beijing, PR China)
General Policy

**IN VIVO** is a multidisciplinary journal designed to bring together original high quality works and reviews on experimental and clinical biomedical research within the frames of human physiology, pathology and disease management. A special focus of the journal is the publication of works on: (a) Experimental development and application of new diagnostic procedures; (b) Pharmacological and toxicological evaluation of new drugs and drug combinations; (c) Clinical trials; (d) Development and characterization of models of biomedical research.

The principal aim of **IN VIVO** is to provide prompt online publication for accepted articles, generally within 1-2 months from final acceptance (3 months from submission).

**Editorial Office:** International Institute of Anticancer Research, 1st km Kapandritou-Kalamou Rd., P.O. Box 22, Kapandriti, Attiki 19014, Greece. Tel: +30 22950 52945, Fax: +30 22950 53389.

**U.S. Branch:** Anticancer Research Inc., USA, 111 Bay Avenue, Highlands, NJ, USA.

**E-mail:** journals@iiar-anticancer.org; IIAR WEBSITES: www.iiar-anticancer.org and www.iiarjournals.org

---

**Selection of Recent Articles**


Oral Recombinant Methioninase Prevents Obesity in Mice on a High Fat Diet. Y. TASHIRO, Q. HAN, Y. TAN, N. SUGISAWA, J. YAMAMOTO, H. NISHINO, S. INUBUSHI, T. HIGUCHI, T. AKI, M. MURAKAMI, R.M. HOFFMAN (San Diego, CA, USA; Tokyo, Japan)

Radical-scavenging and Pro-/anti-inflammatory Activity of Tetracycline and Related Phenolic Compounds With or Without Visible Light Irradiation. Y. MURAKAMI, A. KAWATA, S. SUZUKI, S. FUJISAWA (Sakado, Japan)

TRPV1 Mediates Glucose-induced Insulin Secretion Through Releasing Neuropeptides. B. ZHONG, S. MA, D.H. WANG (East Lansing, MI, USA)

Health-related Quality of Life of Breast Cancer Survivors Attending an Exercise Intervention Study: A Five-year Follow-up. E. ROINE, H. SINTONEN, P.-L. KELLOKUMPU-LEHTINEN, H. PENTTINEN, M. UTRAIINNER, L. VEHMANEN, R. HUOVINEN, R. KAUTIAINNER, R. NIKANDER, C. BLOMOVIST, T. SAARTO (Helsinki; Tampere; Turku; Kuopio; Jyväskylä, Finland)


Symptom Burden in Patients With Reduced Performance Status at the Start of Palliative Radiotherapy. C. NIEDER, T.A. KAMPE (Bodo; Tromsø, Norway)

The Association of MMP7 Genotype With Pterygium. P.-S. HU, Y.-C. WANG, C.-H. LIAO, N.-Y. HSIA, M.-F. WU, J.-S. YANG, C.-C. YU, W.-S. CHANG, D.-T. BAU, C.-W. TSAI (Taichung; Changhua; Taipei; Taiwan, ROC)

Reasons to Reconsider Risk Associated With Power Morcellation of Uterine Fibroids. C. HILZMANN, W. KUEPKER, B. ROMMEL, B. HELMKE, J. BULLERDEK (Rostock; Buehl; Bremen; Stade, Germany)

Chemosuppression of Breast Cancer With Vitamins and Micronutrients: A Concise Review. KEFAH MOKBEL, KINAN MOKBEL (London, UK)

Serum Level of microRNA-375-3p Is not a Reliable Biomarker of Teratoma? G. BELGE, F. GROBELNY, C. MATTHIES, A. RADTKE, K.-P. DIECKMANN (Bremen; Hamburg, Germany)


Erratum .......................................................................................................................................................................................... 6571

Longitudinal Changes in Health-related Quality of Life After 125I Low-dose-rate Brachytherapy for Localized Prostate Cancer. N. OGASAWARA, M. NAKIRI, H. KUROSE, K. UEDA, K. CHIKUI, K. NISHIHARA, M. MATSUO, S. SUEKANE, K. MUROTANI, K. MURAKI, C. HATTORI, E. OGO, T. IGAWA, T. ISHITAKE (Kurume, Japan) .......................................................... 6443


Efficacy of Electrochemotherapy in the Treatment of Cutaneous Melanoma Metastases and Rare Non-melanoma Skin Cancer. L. BORGOGNONI, L. PESCITELLI, G. GERLINI, P. BRANDANI, R. GELLI, V. GIANNOTTI, F. BELLUCCI, S. SESTINI (Florence, Italy) .......................................................... 6485

Efficacy and Safety of Axitinib Therapy After Nivolumab for Patients With Metastatic Renal Cell Cancer. S. YASUOKA, T. YUASA, R. FUJIWARA, Y. KOMAI, N. NUMAO, S. YAMAMOTO, Y. KONDO, J. YONESE (Tokyo, Japan) .......................................................... 6493

Simultaneous Integrated Radiotherapy Boost to the Dominant Intraprostatic Lesion: Final Results of a Phase I/II Trial. M. BUWENGE, A.R. ALITTO, S. CILLA, I. CAPOCACCIA, E. MAZZEO, E. IPPOLITO, G. MANTINI, G. SIEPE, L. CAVALLINI, V. VALENTINI, F. DEODATO, A.G. MORGANTI, G. MACCHIA (Bologna; Rome; Campobasso; Modena, Italy) .......................................................... 6499


Re-Evaluation of Prognostic Factors for Survival After Radiotherapy of Cerebral Gliomas: A Supplementary Analysis to a Previous Study. J. WITTELER, T.W. KJAER, S. TVILSTED, S.E. SCHILD, D. RADES (Lübeck, Germany; Roskilde; Køge, Denmark; Scottsdale, AZ, USA) .......................................................... 6513

Usefulness of Preoperative Endoscopic Fluorescent Clip Marking in Laparoscopic Gastrointestinal Surgery. S. RYU, A. OKAMOTO, K. NAKASHIMA, K. HARA, K. ISHI DA, R. ITO, Y. NAKABAYASHI, K. ETO, T. IKEGAMI (Kawaguchi; Tokyo, Japan) .......................................................... 6517

Impaired Vitamin D Signaling Is Associated With Frequent Development of Renal Cell Tumor in End-stage Kidney Disease. J. DOCS, D. BANYAI, T. FLASKO, A. SZANTO, G. KOVACS (Pecs; Debrecen, Hungary; Heidelberg, Germany) .......................................................... 6525

Impact of Palifermin on Transplant Outcomes in Children and Adolescents Undergoing Allogeneic Hematopoietic Cell Transplantation. K. CZYTEWSKI, R. DĘBSKI, N. BARTOSZEWICZ, E. DEMIDÓWICZ, M. RICHERT-PRZYGOŃSKA, M. ŁĘCKA, S. TARASENKO, J. STYCZYŃSKI (Bydgoszcz, Poland) .......................................................... 6531
High Expression of UBE2B as a Poor Prognosis Factor in Patients With Rectal Cancer Following Chemoradiotherapy. W.-L. HUANG, C.-W. LUO, C.-L. CHOU, C.-C. YANG, T.-J. CHEN, C.-F. LI, M.-R. PAN (Kaohsiung; Tainan, Taiwan, ROC) .............................................................................................................. 6305

Development of an Oncolytic Recombinant Vesicular Stomatitis Virus Encoding a Tumor-suppressor MicroRNA. T. SAKUDA, T. KUBO, M.P. JOHAN, T. FURUTA, T. SAKAGUCHI, N. ADACHI (Hiroshima, Japan; Makassar, Indonesia).................................................................................................................................. 6319


Expression Profile of S100A2 and its Clinicopathological Significance in Renal Cell Carcinoma. T. SUGIYAMA, S. OZONO, H. MIYAKE (Hamamatsu, Japan) ............................................................................ 6337

Potentiation of Differentiation and Apoptosis in a Human Promyelocytic Leukemia Cell Line by Garlic Essential Oil and Its Organosulfur Compounds. S.F.T. AGASSI, T.-M. YEH, C.-D. CHANG, J.-L. HSU, W.-L. SHIH (Pingtung, Taiwan, ROC) ........................................................................................................................ 6345


Clinical Studies

Tertiary Lymphoid Structures in Colorectal Cancer Liver Metastases: Association With Immunological and Clinical Parameters and Chemotherapy Response. A. AHMED, N. HALAMA (Heidelberg; Mainz, Germany)................................. 6367

Sequencing of Sclerosing Microcystic Adenocarcinoma Identifies Mutational Burden and Somatic Variants Associated With Tumorigenesis. R. JIANG, J. MARQUEZ, J.J. TOWER, D. JACOBS, W. CHEN, S. MEHRA, M.L. PRASAD, B.L. JUDSON (New Haven, CT, USA)................................................................................................. 6375

Gastric Cancer Disparities Among Asian American Subpopulations. D. TRUMBULL, R. LEMINI, K. ATTWOOD, M. KUKAR, E. GABRIEL (Gainesville; Jacksonville, FL; Buffalo, NY, USA) .............................................................. 6381

Helicobacter pylori (Hp) IgG ELISA of the New-Generation GastroPanel® Is Highly Accurate in Diagnosis of Hp-Infection in Gastroscopy Referral Patients. M. MAKI, D. SÖDERSTRÖM, L. PALOHEIMO, P. HENDOLIN, O. SUOVANIEMI, K. SYRJÄNEN (Helsinki; Kaarina, Finland)................................................. 6387

Timing of Severe Toxicity from Chemotherapy in Patients With Lung Cancer. K. SJÖGREN, K.A. JACOBSEN, B.H. GRØNBERG, T.O. HALVORSEN (Trondheim, Norway) .............................................................................. 6399

Clinical Significance of Tumour CD44v and MIST1 Expression in Patients With Non-small-cell Lung Cancer. T. NAGASHIMA, T. OSHIMA, Y. HIROSHIMA, T. YOKOSE, T. WOO, Y. RINO, M. MASUDA, Y. MIYAGI, H. ITO, H. NAKAYAMA (Yokohama, Japan) ................................................................. 6407

Thyroid Hormones, Silencing Mediator for Retinoid and Thyroid Receptors and Prognosis in Primary Breast Cancer. B. NISMAN, T.M. ALLWEIS, E. CARMON, L. KADOURI, B. MALK, O. MAIMON, A. MEIEROVICH, T. PERETZ (Jerusalem; Rehovot, Israel) .............................................................................. 6417

Unresectable Chondrosarcomas Treated With Carbon Ion Radiotherapy: Relationship Between Dose-averaged Linear Energy Transfer and Local Recurrence. S. MATSUMOTO, S.H. LEE, R. IMAI, T. INANIWA, N. MATSUFUJI, M. FUKAHORI, R. KOHNO, S. YONAI, N. OKONOGI, S. YAMADA, N. KANEMATSU (Chiba, Japan) ................................................................................................. 6429

Contents continued on the preceding page
A Potential Role of Adhesion Molecules on Lung Metastasis Enhanced by Local Inflammation. H. HORIGUCHI, H. TSUJIMOTO, N. SHINOMIYA, Y. MATSUMOTO, H. SUGASAWA, T. YAMORI, H. MIYAZAKI, D. SAI TOH, Y. KISHI, H. UENO (Saitama; Tokyo, Japan) ........................................................... 6171

Breast Cancer Cells Induce a Pro-inflammatory Response to Mitigate Immune Mediation in a 3D Culture Model. T.N. AUGUSTINE, R. DUARTE, G.P. CANDY (Johannesburg, South Africa) ........................................ 6179

Apoptosis-related Proteins Are Altered by Selective Tyrosine Kinase Inhibitors and Everolimus in HPV-dependent SCC. R. BIRK, A. SCHELL, C. ADERHOLD, S. HOCH, L. HUBER, C.E. MUELLER, A. LAMMERT, C. SCHERL, N. ROTTER, J.U. SOMMER, B. KRAMER (Marburg; Mannheim; Wuppertal, Germany) ........................................................................................................................................ 6195

Protherapeutic Effects and Inactivation of Mammary Carcinoma Cells by a Medical Argon Plasma Device. M.B. STOPE, R. BENOUAHI, C. SANDLER, L. HARALAMBI EV, A. NITSCH, E. EGGER, A. MUSTEA (Bonn; Greifswald; Berlin, Germany) .............................................................................................................. 6205

Expression of IGF-IEc Isoform in Renal Cell Carcinoma Tissues. F. MICHALOPOULOU, C. PETRAKI, A. PHILIPPOU, A. ANALITIS, P. MSAOU EL, M. KOUTSILIERIS (Athens, Greece; Houston, TX, USA) ........ 6213

Frequent MN1 Gene Mutations in Malignant Peripheral Nerve Sheath Tumor. I. KINOSHITA, Y. YAMADA, K. KOHASHI, H. YAMAMOTO, T. IWASAKI, S. ISHIHARA, Y. TODA, Y. ITO, Y. SUSUKI, K. KAWAGUCHI, T. ICHIKI, Y. SATO, M. FUR UE, Y. NAKASHIMA, Y. ODA (Fukuoka, Japan) .................. 6221


3EZ, 20Ac-ingenol-induced Apoptosis in Chemoresistant Cancers With Cyclin D1 Accumulation. S. MIYATA, T. NAKAMURA, S. KITANAKA (Tokyo; Chiba, Japan) ...................................................................................................................... 6237

Involvement of the MicroRNA-1-LITAF Axis in Gastric Cancer Cell Growth and Invasion. Y.-C. CHEN, C.-C. WU, Y.-T. TU, Y.-R. CHEN, M.-C. LEE, K.-W. TSAI (New Taipei City, Taiwan, ROC) ........................................ 6247


Synergistic Antiproliferative Effect of Ribociclib (LEE011) and 5-Fluorouracil on Human Colorectal Cancer. P.-M. LIN, H.-M. LEE, C.-I HUANG, T.-S. TAI, J.-H. CHEN, C.-I CHEN, Y.-C. SU (Kaohsiung, Taiwan, ROC) ........................................................................................................................................ 6265

Use of AKR1C1 and TKTL1 in the Diagnosis of Low-grade Squamous Intraepithelial Lesions from Mexican Women. A. SEQUE DA-JUÁREZ, A. JIMÉNEZ, A. ESPINOSA-MONTESINOS, M.D.C. CARDENAS-AGUAYO, E. RAMÓN-GALLEGOS (Mexico City, México) ...................................................................................................................... 6273

Overexpression of Pyruvate Carboxylase Is Correlated With Colorectal Cancer Progression and Supports Growth of Invasive Colon Cancer HT-29 Cell Line. J. NGAMKHAM, C. THUWAJIT, P. THUWAJIT, P. KHAM WACHIRAPITHAK, K. LERTSUWAN, V. CHAROENSAWAN, S. JITRAPAKDEE (Bangkok; Nakhon Pathom, Thailand) ................................................................. 6285


Contents continued on the preceding page
Experimental Studies

WNT Signaling Driven by R-spondin 1 and LGR6 in High-grade Serous Ovarian Cancer. S. LEE, J. JUN, W.J. KIM, P. TAMAYO, S.B. HOWELL (Seoul, Republic of Korea; San Diego, CA, USA)................................. 6017

Effect of Sex Steroid Hormones on Tongue Cancer Cells In Vitro. J. PELTONEN, K. TUOMAINEN, T. SALLINEN, I. FARESS, I. SULEYMANOVA, A. AL-SAMADI, T. SALO, P. ÅSTRÖM (Helsinki; Oulu, Finland; Åhus, Denmark)...................................................................................................................................... 6029

Characterization of a Novel Barbituric Acid and Two Thiobarbituric Acid Compounds for Lung Cancer Treatment. S.Y. LEE, B. SLAGLE-WEBB, A.K. SHARMA, J.R. CONNOR (Hershey, PA, USA).................................................................................................................................................................. 6039

In Vitro Effect and Mechanism of Action of Ergot Alkaloid Dihydroergocristine in Chemoresistant Prostate Cancer Cells. L. BAI, X. LI, X. MA, R. ZHAO, D. WU (Wuhan; Shanghai; Changchun, PR China; Augusta, GA, USA)................................. 6051

In Vitro Analyses of Interactions Between Colonic Myofibroblasts and Colorectal Cancer Cells for Anticancer Study. M. MUSA, D. OUARET, W.F. BODMER (Kubang Kerian, Malaysia; Oxford, UK)............................ 6063

An Autocrine Role for CXCL1 in Progression of Hepatocellular Carcinoma. K.J.V. DAHLQUIST, L.C. VOTH, A.J. FEE, A.K. STOECKMAN (Saint Paul, MN, USA).......................................................................................................................... 6075

Oral Recombinant Methioninase Sensitizes a Bladder Cancer Orthotopic Xenograft Mouse Model to Low-dose Cisplatinum and Prevents Metastasis. Y. SUN, H. NISHINO, N. SUGISAWA, J. YAMAMOTO, K. HAMADA, G. ZHU, H.I. LIM, R.M. HOFFMAN (San Diego, CA, USA).......................................................................................................................................................... 6083

Inhibition of Bruton’s Tyrosine Kinase Suppresses Cancer Stemness and Promotes Carboplatin-induced Cytotoxicity Against Bladder Cancer Cells. Y. PAN, Y.-H. CHU, S.-C. CHIU, D.-Y. CHO, L.-M. LEE, Y.-C. WEN, J. WHANG-PENG, C.-H. HSIAO, P.-H. SHIH (Taipei; Taichung, Taiwan, ROC)................................. 6093


TYRO3 Truncation Resulting From at(10;15)(p11;q15) Chromosomal Translocation in Pediatric Acute Myeloid Leukemia. M. BRUNETTI, B. ZELLER, A. TIERENS, S. HEIM, F. MICCI, I. PANAGOPOULOS (Oslo, Norway; Toronto, ON, Canada).................................................................................................................................................................. 6115


Synthetic Betulin Derivatives Inhibit Growth of Glioma Cells In Vitro. S.K. KRÓL, E. BĘBENEK, A. SŁAWIŃSKA-BRYCH, M. DOMSZYŃSKA-GRANICZKA, S. BORYCZKA, A. STEPULAK (Lublin; Katowice, Poland).................................................................................................................................................................. 6151


Contents continued on the preceding page